TILA-TACE in Treatment of Hepatocellular Carcinoma

Zhejiang University logo

Zhejiang University

Status

Enrolling

Conditions

Tumor Response Rate
Overall Survival

Treatments

Procedure: TILA-TACE treatment

Study type

Interventional

Funder types

Other

Identifiers

NCT03910140
ZUSAHZUCI201701

Details and patient eligibility

About

To validate the tumor response rate: in the previous study, the investigators showed that TILA-TACE achieved 100% tumor response rate. However, as the study sample size was 40, the investigators need to validate the tumor response rate using a larger sample size; To validate the overall survival: in the previous study, the investigators showed that TILA-TACE significantly prolonged the overall survival of the patients with large and massive tumor. Again, the sample size was small, the investigators need to validate the data using a large sample size.

Enrollment

2,000 estimated patients

Sex

All

Volunteers

No Healthy Volunteers

Inclusion criteria

  • Hepatocellular carcinoma is confirmed by tissue pathology or in accordance with clinical diagnosis standard;
  • ECOG score 0-1;
  • HCC BCLC grading 0, A, B, C;
  • Child-Pugh score prior to therapy A and B;
  • As judged by investigators, the patient can comply with the study protocol;
  • Patient voluntarily participates in this study, understands the process of the study, and is willing to sign the written consent form.

Exclusion criteria

  • HCC BCLC grading D;
  • Child-Pugh score prior to therapy C.

Trial design

Primary purpose

Treatment

Allocation

N/A

Interventional model

Single Group Assignment

Masking

None (Open label)

2,000 participants in 1 patient group

TILA-TACE group
Experimental group
Treatment:
Procedure: TILA-TACE treatment

Trial contacts and locations

0

Loading...

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location

Resources

© Copyright 2024 Veeva Systems